Usage of different lots of RLDs in multistage adaptive studies [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2018-09-20 14:19 (2483 d 06:53 ago) – Posting: # 19294
Views: 2,515

Hi manusyriac,

❝ Can we use different lots of RLDS in multistage studies as the study design requires more than 2 years of shelf-life for RLDs. If it is possible please help me to find any relevant regulatory guidance for the same.


Without being absolutely sure I think this would be ok with most EU authorities for the reasons you state. Less convinced about how HC or FDA or PMDA would see it.
Note that in your case batch and stage will have the same meaning for the product(s) in question.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,697 registered users;
50 visitors (0 registered, 50 guests [including 16 identified bots]).
Forum time: 21:13 CEST (Europe/Vienna)

Anyone who conducts an argument by appealing to authority
is not using his intelligence;
he is just using his memory.    Leonardo da Vinci

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5